Amphastar P (AMPH)vsViatris Inc (VTRS)
AMPH
Amphastar P
$26.68
-2.59%
HEALTHCARE · Cap: $1.03B
VTRS
Viatris Inc
$18.12
-0.82%
HEALTHCARE · Cap: $19.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 1919% more annual revenue ($14.74B vs $730.02M). AMPH leads profitability with a 10.8% profit margin vs -2.8%. VTRS appears more attractively valued with a PEG of 1.05. AMPH earns a higher WallStSmart Score of 59/100 (C).
AMPH
Buy59
out of 100
Grade: C
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+27.6%
Fair Value
$39.51
Current Price
$26.68
$12.83 discount
Margin of Safety
-83.9%
Fair Value
$8.77
Current Price
$18.12
$9.35 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Strong operational efficiency at 21.6%
Reasonable price relative to book value
Areas to Watch
4.7% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
4.9% revenue growth
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMPH
The strongest argument for AMPH centers on Price/Book, P/E Ratio, Operating Margin.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : AMPH
The primary concerns for AMPH are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.
Key Dynamics to Monitor
AMPH profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
AMPH carries more volatility with a beta of 0.92 — expect wider price swings.
AMPH is growing revenue faster at 5.4% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
AMPH scores higher overall (59/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amphastar P
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?